Primary myelofibrosis is characterized by bone marrow fibrosis, splenomegaly and presence of JAK-2 V617F mutation in more than 90% of patients. Ruxolitinib is a Janus kinase inhibitor used for the treatment of primary myelofibrosis. We describe herein a persistent foot ulcer development attributed to ruxolitinib therapy. We are unaware of any previous reports of this phenomenon in the scientific literature. A thorough examination of the lower extremities is perhaps necessary before initiating this oral agent. If ruxolitinib therapy cannot be safely discontinued, diligent wound care and a course of antibiotics are warranted.
CampbellPJGreenAR. The myeloproliferative disorders. N Engl J Med2006; 355: 2452–2466.
2.
VerstovsekSMesaRAGotlibJet al.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med2012; 366: 799–807.
3.
BaxterEJScottLMCampbellPJet al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet2005; 365: 1054–1061.
4.
VainchenkerWDelhommeauFConstantinescuSNet al.New mutations and pathogenesis of myeloproliferative neoplasms. Blood2011; 118: 1723–1735.
5.
HarrisonCKiladjianJ-JAl-AliHKet al.JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med2012; 366: 787–798.
6.
NaranjoCABustoUSellersEMet al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
7.
ShanmugamVKMcnishSSharaNet al.Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi®). J Foot Ankle Surg2013; 52: 781–785.
8.
ChaineBNeonatoMGGirotRet al.Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol2001; 137(4): 467–470.
